サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：緑内障治療薬の世界市場－成長、将来展望、競合分析（2022年～2030年）
市場調査レポート
商品コード
1176523

緑内障治療薬の世界市場－成長、将来展望、競合分析（2022年～2030年）

Glaucoma Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日: | 発行: Acute Market Reports | ページ情報: 英文 118 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
緑内障治療薬の世界市場－成長、将来展望、競合分析（2022年～2030年）
出版日: 2022年08月10日
発行: Acute Market Reports
ページ情報: 英文 118 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

緑内障の高い有病率、診断技術の技術的進歩、治療に対する意識の高まり、診断技術の向上は、市場の成長を促進しています。

当レポートでは、世界の緑内障治療薬市場について調査分析し、競合分析、市場力学、市場分析、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 序文

  • レポートの説明
    • レポートの目的
    • 対象者
    • 主な製品
  • 市場セグメンテーション
  • 調査手法
    • フェーズⅠ－2次調査
    • フェーズⅡ－1次調査
    • フェーズⅢ－専門家による審査
    • 仮定
    • 採用されたアプローチ

第2章 エグゼクティブサマリー

  • 市場スナップショット：世界の緑内障治療薬市場
  • 世界の緑内障治療薬市場（100万米ドル）（2021年）：薬剤クラス別
  • 世界の緑内障治療薬市場（100万米ドル）：地域別
  • 魅力的な投資提案（2021年）：地域別

第3章 緑内障治療薬市場：競合分析

  • 主要な緑内障治療薬市場ベンダーの市場ポジショニング
  • 緑内障治療市場ベンダーが採用する戦略
  • 主要な業界戦略
  • 階層分析：2021年と2030年の比較

第4章 緑内障治療薬市場：マクロ分析と市場力学

  • イントロダクション
  • 世界の緑内障治療薬の市場金額（100万米ドル）（2020年～2030年）
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因と抑制要因の影響分析
  • シーソー分析

第5章 緑内障治療薬市場、米ドル（100万）（2020年～2030年）：薬剤クラス別

  • 市場概要
  • 成長と収益分析：2021年と2030年の比較
  • 市場セグメンテーション
    • プロスタグランジン類似体
    • ベータ遮断薬
    • アルファアドレナリンアゴニスト
    • 炭酸脱水酵素阻害剤
    • 固定用量配合剤

第6章 北米の緑内障治療薬市場、米ドル（100万）（2020年～2030年）

第7章 英国および欧州連合の緑内障治療薬市場、米ドル（100万）（2020年～2030年）

第8章 アジア太平洋の緑内障治療薬市場、米ドル（100万）（2020年～2030年）

第9章 ラテンアメリカの緑内障治療薬市場、米ドル（100万）（2020年～2030年）

第10章 中東およびアフリカの緑内障治療薬市場、米ドル（100万）（2020年～2030年）

第11章 企業プロファイル

  • Aerie Pharmaceuticals
  • Akorn, Inc.
  • Allergan plc.
  • Bausch & Lomb Incorporated
  • Inotek Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Santen Pharmaceuticals Co. Ltd
  • Teva Pharmaceuticals
図表

List of Tables

  • TABLE 1 Global Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 2 North America Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 3 U.S. Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 4 Canada Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 5 Rest of North America Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 6 UK and European Union Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 7 UK Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 8 Germany Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 9 Spain Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 10 Italy Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 11 France Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 12 Rest of Europe Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 13 Asia Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 14 China Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 15 Japan Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 16 India Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 17 Australia Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 18 South Korea Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 19 Latin America Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 20 Brazil Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 21 Mexico Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 22 Rest of Latin America Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 23 Middle East and Africa Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 24 GCC Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 25 Africa Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 26 Rest of Middle East and Africa Glaucoma Therapeutics Market By Drug Class, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Glaucoma Therapeutics Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Glaucoma Therapeutics Market: Quality Assurance
  • FIG. 5 Global Glaucoma Therapeutics Market, By Drug Class, 2021
  • FIG. 6 Global Glaucoma Therapeutics Market, By Geography, 2021
  • FIG. 7 Market Geographical Opportunity Matrix - Global Glaucoma Therapeutics Market, 2021
  • FIG. 8 Market Positioning of Key Glaucoma Therapeutics Market Players, 2021
  • FIG. 9 Global Glaucoma Therapeutics Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 10 Global Glaucoma Therapeutics Market, By Drug Class, 2021 Vs 2030, %
  • FIG. 11 U.S. Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 12 Canada Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 13 Rest of North America Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 14 UK Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 15 Germany Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 16 Spain Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 17 Italy Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 18 France Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 19 Rest of Europe Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 20 China Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 21 Japan Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 22 India Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 23 Australia Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 24 South Korea Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Asia Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 26 Brazil Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 27 Mexico Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Latin America Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 29 GCC Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 30 Africa Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 31 Rest of Middle East and Africa Glaucoma Therapeutics Market (US$ Million), 2020 - 2030
目次
Product Code: 137443-08-22

Glaucoma is chronic, degenerative disorder that damages the eye's optic nerve, may result in vision loss and blindness. Factors such, high prevalence of glaucoma, technological advancement in diagnostic technique, rising treatment awareness are driving the market growth of glaucoma therapeutics globally.

The report titled, "Glaucoma Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2022-2030" offers strategic insights into the overall glaucoma therapeutics market along with the market size and estimates for the duration 2020 to 2030. The research study covers in-depth analysis of market segments based on drug class and different geographical regions.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global glaucoma therapeutics market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global glaucoma therapeutics market. This report concludes with company profiles section that highlights major information about the key players engaged in global glaucoma therapeutics market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global glaucoma therapeutics market, offering market size and estimates for the period from 2020 to 2030, keeping in mind the above-mentioned factors.

Glaucoma is a chronic, degenerative condition that damages the eye's optic nerve, resulting in vision loss and blindness. Factors such as increase in prevalence of eye disorders, significant unmet medical needs and rise in the incidence of age-related eye disorders are driving the market growth of glaucoma therapeutics globally. It is observed that in the year 2016, prostaglandin analogs was largest revenue generating segment because these are widely prescribed first-line treatments for glaucoma. Different studies indicated that fixed-dose combination such as Dorzolamide and Timolol, Latanoprost and Timolol, Brimonidine and Timolol are widely used in market. Patient adherence is more for fixed-dose combination as they reduces the risk of medication washout and also decrease daily topical preservative load. It is observed that beta blockers is second major revenue generating segment, they may be used alone or combined with other medications. They lower the pressure inside the eye and are generally used to treat open-angle glaucoma. Some adverse effects associated with the use of alpha-adrenergic agonists include increase in heart rate and blood pressure negatively impacting the growth of glaucoma therapeutic market.

In the base year 2021, North America dominated the glaucoma therapeutics market in terms of revenue and it is anticipated that it will show steady growth during forecast period of 2022-2030. Factors such as rising geriatric population, upsurge in funding by government agencies and private organizations in healthcare system, increasing incidence of eye disorders, improved diagnostic techniques drive the growth of glaucoma therapeutics market in North America. Europe is the second largest revenue generating regional market for glaucoma therapeutics. U.K., Germany and France are major revenue contributing countries in Europe. It is observed that Middle East and Africa is hold smallest market share and it is anticipated that it will show sluggish market growth during forecast period. Comparatively lower cost of treatment medication hinder the market growth of glaucoma therapeutics in Middle East and Africa. Currently, Asia Pacific is not a major revenue generating segment. However, it is anticipated that it will experience a significant growth during the forecast period. Factors such as increasing population, continuous economic development and developing healthcare infrastructure would contribute the market growth in Asia Pacific during forecast period.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Glaucoma Therapeutics market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Glaucoma Therapeutics market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

  • Prostaglandins Analogs
  • Beta Blockers
  • Alpha-adrenergic Agonists
  • Carbonic Anhydrase Inhibitors
  • Fixed-dose Combinations

Region Segment (2020-2030; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

  • Pre COVID-19 situation
  • Post COVID-19 situation

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Glaucoma Therapeutics market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Glaucoma Therapeutics market?
  • Which is the largest regional market for Glaucoma Therapeutics market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Glaucoma Therapeutics market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Glaucoma Therapeutics market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Glaucoma Therapeutics Market
  • 2.2. Global Glaucoma Therapeutics Market, By Drug Class, 2021 (US$ Million)
  • 2.3. Global Glaucoma Therapeutics Market, By Geography, 2021 (US$ Million)
  • 2.4. Attractive Investment Proposition by Geography, 2021

3. Glaucoma Therapeutics Market: Competitive Analysis

  • 3.1. Market Positioning of Key Glaucoma Therapeutics Market Vendors
  • 3.2. Strategies Adopted by Glaucoma Therapeutics Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Glaucoma Therapeutics Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Glaucoma Therapeutics Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Prostaglandins Analogs
    • 5.3.2. Beta Blockers
    • 5.3.3. Alpha-adrenergic Agonists
    • 5.3.4. Carbonic Anhydrase Inhibitors
    • 5.3.5. Fixed-dose Combinations

6. North America Glaucoma Therapeutics Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
  • 6.3.Glaucoma Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.North America
      • 6.3.1.1. U.S.
        • 6.3.1.1.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
      • 6.3.1.2. Canada
        • 6.3.1.2.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
      • 6.3.1.3. Rest of North America
        • 6.3.1.3.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)

7. UK and European Union Glaucoma Therapeutics Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
  • 7.3.Glaucoma Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.UK and European Union
      • 7.3.1.1. UK
        • 7.3.1.1.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.2. Germany
        • 7.3.1.2.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.3. Spain
        • 7.3.1.3.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.4. Italy
        • 7.3.1.4.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.5. France
        • 7.3.1.5.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.6. Rest of Europe
        • 7.3.1.6.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)

8. Asia Pacific Glaucoma Therapeutics Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
  • 8.3.Glaucoma Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Asia Pacific
      • 8.3.1.1. China
        • 8.3.1.1.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.2. Japan
        • 8.3.1.2.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.3. India
        • 8.3.1.3.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.4. Australia
        • 8.3.1.4.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.5. South Korea
        • 8.3.1.5.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.6. Rest of Asia Pacific
        • 8.3.1.6.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)

9. Latin America Glaucoma Therapeutics Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
  • 9.3.Glaucoma Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Latin America
      • 9.3.1.1. Brazil
        • 9.3.1.1.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
      • 9.3.1.2. Mexico
        • 9.3.1.2.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
      • 9.3.1.3. Rest of Latin America
        • 9.3.1.3.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)

10. Middle East and Africa Glaucoma Therapeutics Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
  • 10.3.Glaucoma Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 10.3.1.Middle East and Africa
      • 10.3.1.1. GCC
        • 10.3.1.1.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
      • 10.3.1.2. Africa
        • 10.3.1.2.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)
      • 10.3.1.3. Rest of Middle East and Africa
        • 10.3.1.3.1. Glaucoma Therapeutics Market: By Drug Class, 2020-2030, USD (Million)

11. Company Profile

  • 11.1. Aerie Pharmaceuticals
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Akorn, Inc.
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. Allergan plc.
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. Bausch & Lomb Incorporated
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. Inotek Pharmaceuticals
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. Merck & Co., Inc.
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. Novartis AG
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Pfizer Inc.
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. Santen Pharmaceuticals Co. Ltd
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives
  • 11.10. Teva Pharmaceuticals
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Initiatives